Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusion.
作者信息
Shabani Minoosh, Shokouhi Shervin, Moradi Omid, Saffaei Ali, Sahraei Zahra
机构信息
Department of Infectious Diseases and Tropical Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
出版信息
J Med Virol. 2021 Jan;93(1):69-70. doi: 10.1002/jmv.26124. Epub 2020 Jun 19.
Abstract
摘要
相似文献
1
Tocilizumab administration in patients with SARS-CoV-2 infection: Subcutaneous injection vs intravenous infusion.托珠单抗用于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染患者：皮下注射与静脉输注对比
J Med Virol. 2021 Jan;93(1):69-70. doi: 10.1002/jmv.26124. Epub 2020 Jun 19.
2
Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies.托珠单抗治疗 COVID-19：皮下注射与静脉输注治疗的比较。
Int J Infect Dis. 2020 Dec;101:59-64. doi: 10.1016/j.ijid.2020.09.1447. Epub 2020 Sep 28.
3
Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.托珠单抗治疗细胞因子风暴综合征的 SARS-CoV-2 患者：一项叙述性综述。
Rev Recent Clin Trials. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954.
4
An unfavourable outcome following switching intravenous abatacept and tocilizumab to subcutaneous forms during the COVID-19 pandemic.在新冠疫情期间，将静脉注射阿巴西普和托珠单抗换成皮下注射剂型后出现不良结局。
Rheumatology (Oxford). 2021 Feb 1;60(2):977-979. doi: 10.1093/rheumatology/keaa653.
5
Tocilizumab alleviates cytokine storm with acute respiratory distress syndrome in severe SARS-CoV-2 infection in Taiwan.托珠单抗可缓解台湾地区严重SARS-CoV-2感染伴急性呼吸窘迫综合征的细胞因子风暴。
Intern Med J. 2021 Sep;51(9):1543-1544. doi: 10.1111/imj.15335.
6
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.托珠单抗治疗的 2019 冠状病毒病成年患者的临床特征和生存预测因素。
J Autoimmun. 2020 Nov;114:102512. doi: 10.1016/j.jaut.2020.102512. Epub 2020 Jul 3.
7
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19.卡司瑞韦单抗和伊德维单抗皮下注射或静脉给药与 COVID-19 成年患者临床结局的关联。
JAMA Netw Open. 2022 Apr 1;5(4):e226920. doi: 10.1001/jamanetworkopen.2022.6920.
8
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
9
Effect of subcutaneous vs. intravenous tocilizumab in patients with severe COVID-19: a systematic review.皮下注射与静脉注射托珠单抗治疗重症 COVID-19 患者的效果：系统评价。
Eur J Clin Pharmacol. 2024 Oct;80(10):1523-1530. doi: 10.1007/s00228-024-03719-0. Epub 2024 Jun 27.
10
Use of intravenous tocilizumab in pregnancy for severe coronavirus disease 2019 pneumonia: two case reports.妊娠期静脉注射托珠单抗治疗严重 2019 冠状病毒病肺炎：两例报告。
J Med Case Rep. 2021 Aug 7;15(1):426. doi: 10.1186/s13256-021-03010-1.
引用本文的文献
1
A meta-analysis of granulocyte-macrophage colony-stimulating factor (GM-CSF) antibody treatment for COVID-19 patients.一项关于粒细胞巨噬细胞集落刺激因子（GM-CSF）抗体治疗COVID-19患者的荟萃分析。
Ther Adv Chronic Dis. 2021 Aug 20;12:20406223211039699. doi: 10.1177/20406223211039699. eCollection 2021.
2
The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19).血红素加氧酶 1（HMOX1）通路作为 2019 年新型冠状病毒（COVID-19，即 SARS-CoV-2）治疗和预防的有前途靶点。
Int J Mol Sci. 2020 Sep 3;21(17):6412. doi: 10.3390/ijms21176412.
3
Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.托珠单抗治疗 COVID-19 的疗效：一项非对照、前瞻性临床试验。
Int Immunopharmacol. 2020 Nov;88:106869. doi: 10.1016/j.intimp.2020.106869. Epub 2020 Aug 4.
本文引用的文献
1
Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia.皮下注射托珠单抗在新冠肺炎肺炎患者中的应用。
J Med Virol. 2021 Jan;93(1):32-34. doi: 10.1002/jmv.26016. Epub 2020 Sep 30.
2
Tocilizumab treatment in COVID-19: A single center experience.托珠单抗治疗 COVID-19：单中心经验。
J Med Virol. 2020 Jul;92(7):814-818. doi: 10.1002/jmv.25801. Epub 2020 Apr 15.
3
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
4
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA).皮下注射托珠单抗与静脉注射托珠单抗联合传统改善病情抗风湿药治疗类风湿关节炎患者97周时的疗效和安全性（SUMMACTA研究）
Ann Rheum Dis. 2016 Jan;75(1):68-74. doi: 10.1136/annrheumdis-2015-207281. Epub 2015 Jun 8.
5
Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.成人危重症患者的药物吸收、分布、代谢和排泄考虑因素。
Expert Opin Drug Metab Toxicol. 2013 Sep;9(9):1067-84. doi: 10.1517/17425255.2013.799137. Epub 2013 May 17.
6
Pharmacokinetics and pharmacodynamics of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, following single-dose administration by subcutaneous and intravenous routes to healthy subjects.托珠单抗（一种人源化抗白细胞介素-6受体单克隆抗体）经皮下和静脉途径单剂量给药于健康受试者后的药代动力学和药效学。
Int J Clin Pharmacol Ther. 2013 Jun;51(6):443-55. doi: 10.5414/CP201819.
Zotero 插件